Empagliflozin and Sympathetic Nerve Traffic

• Status: Completed
• Trial end date: 2020-04-20
• Target enrollment: 0
• Participant gender: All

Summary

In this study the effects of the Inhibition of the Sodium-Glucose Linked Transporter 2 in the kidney with empagliflozin compared to hydrochlorothiazide on blood pressure and on central sympathic nervous activity will be examined.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH
• Treatments: Empagliflozin; Hydrochlorothiazide

Criteria

Inclusion Criteria:

• women and men >= 50 and <= 80 years of age

• type 2 diabetes mellitus for >=2 years

• only metformin monotherapy is allowed; metformin dose must have been stable for >=12 weeks

Exclusion Criteria:

• previous empagliflozin treatment within the last 3 months

• heart failure NYHA II - IV

• subjects who have received any investigational medicinal product or have used any investigational medical device within 30 days prior to the screening visit, or who are actively participating in any investigational medicinal product or medical device trial, or who are scheduled for any such trial during the course of the trial.